IDNA250516C20000
- 0.00
- 0.000.00%
Ishares Gold Trust Genomics Immunology And Healthcare Etf Newsroom
Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat
Exelixis Analyst Ratings
Exelixis Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance With Its Midpoint Above Estimates. The Company, Acting as a Collaboration Partner of Invenra, Initiated the...
BEIGENE's Q1 loss narrowed to 94.503 million yuan, with Baiyueze and Baizean sales revenue increasing.
In the first quarter of 2025, BEIGENE achieved revenue of 8.048 billion yuan, a year-on-year increase of 50.2%; the net income attributable to the parent was a loss of 94.503 million yuan, compared to a loss of 1.908 billion yuan in the same period last year; In recent years, with policy support, China's Innovative Drugs Industry has entered a period of rapid development. In 2024, the industry will usher in a new round of policy dividends, and the research and development results of domestic Innovative Drugs will experience explosive growth.
Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors
Earnings Preview: BeiGene
Earnings Scheduled For May 13, 2025
List of conversion stocks (Part 2) [Parabolic Signal conversion stocks list]
○ List of stocks changing to Sell market Code Stock Name Closing Price SAR Main Board <1414> ShoBond 4988 5339 <1813> Fudo Tetra 22032391 <2154> Open UP 17771890 <2201> Morinaga Confectionery 25002606 <2229> Calbee 28972943 <2282> Nippon Ham 53245530 <2325> NJS 39454215 <2378> Renaissance
Exploring Exelixis's Earnings Expectations
VIS---In the first quarter, collaborative drug development research with each partner is progressing as planned, but there is a deficit.
Veritas In Silico <130A> announced its financial results for the first quarter of the fiscal year ending December 2025 (January-March 2025) on the 9th. Business revenue was 0.024 billion yen, a decrease of 25.0% compared to the same period last year, with an operating loss of 0.081 billion yen (compared to a loss of 0.065 billion yen in the same period last year), an ordinary loss of 0.079 billion yen (compared to a loss of 0.087 billion yen), and a net quarterly loss of 0.079 billion yen (compared to a loss of 0.087 billion yen). In the company's mRNA-targeted small molecule drug discovery business, the drug discovery platform...
Stocks that moved and those that were traded in the front market.
* Imagica G <6879> 656 K - The announcement of the MBO aligns the TOB price at 795 yen. * Nisshin <9066> 6350 K - Reports suggest that an MBO is under consideration. * Anest Iwata <6381> 1403 +300 Due to the adoption of DOE, a significant increase in dividends is planned for this term. * Cresco <4674> 1516 +300 The announcement of a double-digit profit outlook for this term and share buyback. * Mitsui Financial Group <7322> 2721 +500 Significant profit growth forecast and increased dividends for this term.
Earnings Week Ahead: PLUG, CSCO, WMT, BABA, AMT, JD, TCEHY, and More
List of cloud penetration stocks [Ichimoku Kinko Hyo - List of cloud penetration stocks]
○ List of stocks breaking through the clouds in the market Code Stock Name Closing Price Leading Span A Leading Span B Tokyo Main Board <1301> Kyokuyo 4285 4278.75 4182.5 <1417> Mirait One 2308 2230 292.5 <1721> Comsys HD 3265 3247.5 3248.5 <1929> Nittoku Construction 1055 1050.5 1032.5 <1979> Taiki Corporation 2370 2345.
RBC Capital Maintains Outperform on BeiGene, Lowers Price Target to $311
BeiGene Analyst Ratings
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
Revolution Medicines Analyst Ratings
Revolution Medicines Outlines 2025 Focus on RAS(ON) Inhibitors in Key Cancer Trials
12 Health Care Stocks Moving In Wednesday's After-Market Session
BeiGene Targets $4.9B-$5.3B Revenue for 2025 With Strong BRUKINSA and Pipeline Growth